New drug shows promise for Hard-to-Treat breast cancer
NCT ID NCT06686394
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times
Summary
This study is testing a new drug called patritumab deruxtecan in people with a type of advanced breast cancer (HER2-positive) that cannot be removed by surgery or has spread to other parts of the body. The main goals are to check the drug's safety and see if it can shrink or stop the cancer. About 81 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 0031)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Centre Hospitalier de l'Université de Montréal ( Site 0004)
RECRUITINGMontreal, Quebec, H2X 3E4, Canada
Contact Phone: •••-•••-••••
-
Dana-Farber Cancer Institute ( Site 0050)
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Inova Schar Cancer Institute ( Site 0051)
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-••••
-
Jewish General Hospital ( Site 0003)
RECRUITINGMontreal, Quebec, H3T 1E2, Canada
Contact Phone: •••-•••-••••
-
Kingston General Hospital ( Site 0061)
RECRUITINGKingston, Ontario, K7L 2V7, Canada
Contact Phone: •••-•••-••••
-
Nagoya City University Hospital ( Site 0020)
RECRUITINGNagoya, Aichi-ken, 467-8602, Japan
Contact Phone: •••-•••-••••
-
Princess Margaret Cancer Centre ( Site 0001)
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-••••
-
Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
RECRUITINGGreenville, South Carolina, 29605, United States
Contact Phone: •••-•••-••••
-
Rabin Medical Center ( Site 0012)
RECRUITINGPetah Tikva, 4941492, Israel
Contact Phone: •••-•••-••••
-
Rambam Health Care Campus ( Site 0011)
RECRUITINGHaifa, 3109601, Israel
Contact Phone: •••-•••-••••
-
Rutgers Cancer Institute of New Jersey ( Site 0052)
RECRUITINGNew Brunswick, New Jersey, 08901, United States
Contact Phone: •••-•••-••••
-
Seoul National University Hospital ( Site 0030)
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-••••
-
Sheba Medical Center ( Site 0010)
RECRUITINGRamat Gan, 5265601, Israel
Contact Phone: •••-•••-••••
-
St Bartholomew s Hospital ( Site 0040)
RECRUITINGLondon, London, City of, EC1A 7BE, United Kingdom
Contact Phone: •••-•••-••••
-
The Beatson West of Scotland Cancer Centre ( Site 0043)
RECRUITINGGlasgow, Glasgow City, G12 0YN, United Kingdom
Contact Phone: •••-•••-••••
-
University College London Hospital ( Site 0041)
RECRUITINGLondon, Camden, NW1 2PG, United Kingdom
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.